L-J Zhao1, P Zhao, Q-L Chen, H Ren, W Pan, Z-T Qi. 1. Department of Microbiology, State Key Laboratory of Medical Immunology, Second Military Medical University, Shanghai, China.
Abstract
OBJECTIVE: Hepatitis C virus (HCV) is a major pathogenic factor of liver diseases. During HCV infection, interaction of the envelope protein E2 of the virion, with target cells, is a crucial process for viral penetration into the cell and its propagation. We speculate that such interaction may trigger early signalling events required for HCV infection. MATERIALS AND METHODS: Human liver cell line L-02 was treated with HCV E2. The kinase phosphorylation levels of mitogen-activated protein kinase (MAPK) signalling pathways in the treated cells were analyzed by Western blotting. The proliferation of the E2-treated cells was evaluated by MTT assay. RESULTS: HCV E2 was shown to be an efficient activator for MAPK pathways. Levels of phosphorylation of upstream kinases Raf-1 and MEK1/2 were seen to be elevated following E2 treatment and similarly, phosphorylation levels of downstream kinases MAPK/ERK and p38 MAPK also increased in response to E2 treatment, and specificity of kinase activation by E2 was confirmed. E2-induced MAPK/ERK activation was inhibited by the MEK1/2 inhibitor U0126 in a concentration-dependent manner. Blockage of relevant cellular receptors reduced activation of Raf-1, MEK1/2, MAPK/ERK and p38 MAPK by E2, indicating efflux of the E2 signal from extracellular to the intracellular spaces. Thus, kinase cascades of MAPK pathways were continuously affected by E2 presence. Moreover, enhancement of cell proliferation by E2 appeared to be associated with the dynamic phosphorylation of MAPK/ERK and p38 MAPK. CONCLUSION: These results suggest that MAPK signalling pathways triggered by E2 may be a potential target for prevention of HCV infection.
OBJECTIVE:Hepatitis C virus (HCV) is a major pathogenic factor of liver diseases. During HCV infection, interaction of the envelope protein E2 of the virion, with target cells, is a crucial process for viral penetration into the cell and its propagation. We speculate that such interaction may trigger early signalling events required for HCV infection. MATERIALS AND METHODS:Human liver cell line L-02 was treated with HCV E2. The kinase phosphorylation levels of mitogen-activated protein kinase (MAPK) signalling pathways in the treated cells were analyzed by Western blotting. The proliferation of the E2-treated cells was evaluated by MTT assay. RESULTS:HCV E2 was shown to be an efficient activator for MAPK pathways. Levels of phosphorylation of upstream kinases Raf-1 and MEK1/2 were seen to be elevated following E2 treatment and similarly, phosphorylation levels of downstream kinases MAPK/ERK and p38 MAPK also increased in response to E2 treatment, and specificity of kinase activation by E2 was confirmed. E2-induced MAPK/ERK activation was inhibited by the MEK1/2 inhibitor U0126 in a concentration-dependent manner. Blockage of relevant cellular receptors reduced activation of Raf-1, MEK1/2, MAPK/ERK and p38 MAPK by E2, indicating efflux of the E2 signal from extracellular to the intracellular spaces. Thus, kinase cascades of MAPK pathways were continuously affected by E2 presence. Moreover, enhancement of cell proliferation by E2 appeared to be associated with the dynamic phosphorylation of MAPK/ERK and p38 MAPK. CONCLUSION: These results suggest that MAPK signalling pathways triggered by E2 may be a potential target for prevention of HCV infection.
Authors: Jeffrey Hildesheim; Dmitry V Bulavin; Miriam R Anver; W Gregory Alvord; M Christine Hollander; Lilit Vardanian; Albert J Fornace Journal: Cancer Res Date: 2002-12-15 Impact factor: 12.701
Authors: Emmanuel G Cormier; Fay Tsamis; Francis Kajumo; Robert J Durso; Jason P Gardner; Tatjana Dragic Journal: Proc Natl Acad Sci U S A Date: 2004-05-03 Impact factor: 11.205
Authors: M F Favata; K Y Horiuchi; E J Manos; A J Daulerio; D A Stradley; W S Feeser; D E Van Dyk; W J Pitts; R A Earl; F Hobbs; R A Copeland; R L Magolda; P A Scherle; J M Trzaskos Journal: J Biol Chem Date: 1998-07-17 Impact factor: 5.157
Authors: Andrew Macdonald; Katherine Crowder; Andrew Street; Christopher McCormick; Kalle Saksela; Mark Harris Journal: J Biol Chem Date: 2003-03-05 Impact factor: 5.157
Authors: Wenyu Lin; Wei-Lun Tsai; Run-Xuan Shao; Guoyang Wu; Lee F Peng; Lydia L Barlow; Woo Jin Chung; Leiliang Zhang; Hong Zhao; Jae-Young Jang; Raymond T Chung Journal: Gastroenterology Date: 2010-03-12 Impact factor: 22.682
Authors: Jessica L Reynolds; Supriya D Mahajan; Ravikunar Aalinkeel; B Nair; Donald E Sykes; Stanley A Schwartz Journal: Immunol Invest Date: 2009 Impact factor: 3.657
Authors: Miguel Prudêncio; Cristina D Rodrigues; Michael Hannus; Cécilie Martin; Eliana Real; Lígia A Gonçalves; Céline Carret; Robert Dorkin; Ingo Röhl; Kerstin Jahn-Hoffmann; Adrian J F Luty; Robert Sauerwein; Christophe J Echeverri; Maria M Mota Journal: PLoS Pathog Date: 2008-11-07 Impact factor: 6.823